로딩 중…
지수 로딩 중…
Dx & Vx Co., Ltd.
180400· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩2,330-3.32%
2026-06-19
Price Chart
Dx & Vx Co., Ltd.+15.63%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 229.34B KRW |
| Revenue | 28.48B KRW |
| Net Income | -28.68B KRW |
| Total Assets | 115.39B KRW |
| Net Assets | 90.79B KRW |
| Employees | 121 |
| Value | |
| P/B | 2.53x |
| P/S | 8.05x |
| FCF Yield | -8.22% |
| Profitability | |
| ROE | -31.59% |
| ROA | -24.86% |
| Op. Margin | -80.35% |
| Revenue Growth | -11.60% |
| Financial Health | |
| Debt Ratio | 127.10% |
| Total Debt | 16.68B KRW |
| FCF | -18.85B KRW |
| Cash | 62.23B KRW |
| Current Ratio | 5.08x |
| Performance | |
| 1Y Return | 15.63% |
| 1M Return | -27.98% |
| From 52W High | -56.53% |
| 1Y MDD | -54.40% |
| Trading | |
| Volume | 176,605 shares |
| Foreign Own. | 5.18% |
| Per Share | |
| EPS | -456 KRW |
| BPS | 904 KRW |
Company Info
DXVX, established in 2001, is a bio-healthcare specialized company that listed on KOSDAQ in 2015. It has expanded its business through the acquisition of Korea Biopharm in 2022, and the establishment of a Chinese subsidiary and acquisition of Evixgen in 2023. The medical diagnostics division focuses on NGS and DNA chip-based genomic diagnostics, along with the development and manufacturing of PCR molecular diagnostic and rapid immune diagnostic kits. The new drug development division aims to reduce financial risk by developing diverse pipelines and implementing stage-by-stage license transfers. DXVX is headquartered in Geumcheon-gu, Seoul.